Literature DB >> 28541766

The clinical utility of vestibular autorotation test in patients with vestibular migraine.

Yogun Thungavelu1, Wei Wang2, Peng Lin2, Taisheng Chen2, Kaixu Xu2.   

Abstract

OBJECTIVE: To investigate the characteristics and clinical utility of vestibular autorotation test (VAT) in patients with vestibular migraine.
METHODS: This study included two groups, an experimental group (441 patients) and a control group (65 healthy subjects). Both groups undertook VAT; the parameters evaluated were horizontal gain/phase, vertical gain/phase and asymmetry. The differences in VAT results between the two groups were investigated.
RESULTS: There were no statistical differences between the VAT data of the control group when compared to the reference value from the manufacturer (p > .05). There were statistically significant differences in VAT results between the experimental and control group, namely elevated horizontal gain at frequency 2, 3, 4 and 5 Hz, horizontal phase delay at frequency 2, 4, 5 and 6 Hz, elevated vertical gain at frequency 2 6Hz and vertical phase delay at frequency 4 6Hz.
CONCLUSION: The results of this study using VAT in VM patients demonstrate elevated horizontal gain, vertical gain and delay in horizontal phase, vertical phase. We suggest the application of VAT as a diagnostic tool which may provide objective evidence that can contribute to the diagnosis of VM and also in differential diagnosis.

Entities:  

Keywords:  Migraine; dizziness; vestibular autorotation test; vestibular migraine; vestibular test; vestibulo-ocular reflex

Mesh:

Year:  2017        PMID: 28541766     DOI: 10.1080/00016489.2017.1331375

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  Vestibular Autorotation Test: The Differences in Peripheral and Central Acute Vestibular Syndrome.

Authors:  Nan Guo; Lijing Zhou; Yu Zhang; Xiuyu Fan
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-13       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.